Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827482) titled 'Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma' on Sept. 7.

Study Type: Observational

Primary Sponsor: First Affiliated Hospital of Fujian Medical University

Condition: Metastatic Renal Cell Carcinoma

Intervention: Diagnostic Test: Pretreatment 18F-FDG PET/CT

Recruitment Status: Not recruiting

Date of First Enrollment: June 1, 2019

Target Sample Size: 228

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07827482

Published by HT Digital Content Services with permissio...